Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the safety and efficacy of lubiprostone in patients with chronic idiopathic constipation (CIC)

Trial Profile

Multi-center, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the safety and efficacy of lubiprostone in patients with chronic idiopathic constipation (CIC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lubiprostone (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories; Sucampo Pharmaceuticals
  • Most Recent Events

    • 05 Aug 2011 The review process for the New Drug Application (NDA) in Japan, submitted to the Japanese Pharmaceuticals and Medical Devices Agency in September 2010, is proceeding as expected, according to a Sucampo Pharmaceuticals media release.
    • 05 Aug 2011 Sucampo Pharmaceuticals has filed a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA), based on the results of the two pivotal trial in the USA and Japan.
    • 10 May 2011 Results presented at Digestive Disease Week 2011.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top